{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:55:13Z","timestamp":1726437313780},"reference-count":54,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1554,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1521-0391.2011.00139.x","type":"journal-article","created":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T12:40:31Z","timestamp":1306845631000},"page":"312-318","source":"Crossref","is-referenced-by-count":19,"title":["Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment"],"prefix":"10.1111","volume":"20","author":[{"given":"Steven L.","family":"Batki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"Canfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ploutz-Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1089-3261(02)00078-8","article-title":"Appendix: The National Institutes of Health Consensus Development Conference management of hepatitis","volume":"7","author":"Seeff","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Inter Med"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ADT.0b013e3181343614","article-title":"Prevalence and incidence of hepatitis C in drug users: A review","volume":"7","author":"Abou-Saleh","year":"2008","journal-title":"Addict Disord Ther Treat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J069v20n01_03","article-title":"Hepatitis C in methadone maintenance patients: Prevalence and public policy implications","volume":"20","author":"McCarthy","year":"2001","journal-title":"J Addict Dis"},{"issue":"S1","key":"10.1111\/j.1521-0391.2011.00139.x-BIB6|cit6","first-page":"S18","article-title":"Public health and hepatitis C","volume":"91","author":"Patrick","year":"2000","journal-title":"Can J Public Health"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"A55","DOI":"10.1016\/S0016-5085(08)80271-5","article-title":"Pegylated (40kDa) (PEGASYS) interferon alfa-2a in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled, multicenter study","volume":"120","author":"Fried","year":"2001","journal-title":"Gastroenterol"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"PEG-interferon alfa-2B plus ribavirin compared with interferon alfa-2B plus ribavirin for initial treatment of chronic hepatitis C: A randomized trail","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet."},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs."},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archpsyc.1982.04290020027006","article-title":"Heterogeneity of psychiatric diagnosis in treated opiate addicts","volume":"39","author":"Rounsaville","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1997.01830130077015","article-title":"Psychiatric and substance use comorbidity among treatment-seeking opioid abusers","volume":"54","author":"Brooner","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"4S","key":"10.1111\/j.1521-0391.2011.00139.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/00002508-200207001-00003","article-title":"Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients","volume":"18","author":"Strain","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.drugalcdep.2003.11.014","article-title":"Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program","volume":"74","author":"Kidorf","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB15|cit15","first-page":"126","article-title":"Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment, tenure and infectious diseases in an Israeli methadone maintenance clinic","volume":"43","author":"Gelkopf","year":"2006","journal-title":"Isr J Psych Relat Sci"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1615\/CritRevNeurobiol.v19.i2-3.20","article-title":"Psychiatric implications of hepatitis C treatment","volume":"19","author":"Giunta","year":"2007","journal-title":"Crit Rev Neurobiol"},{"issue":"S5","key":"10.1111\/j.1521-0391.2011.00139.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1086\/427443","article-title":"Psychiatric barriers to readiness for treatment for hepatitis C virus (HCV) infection among injection drug users: Clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital","volume":"40","author":"Scheft","year":"2005","journal-title":"Clin Infect Dis."},{"issue":"S5","key":"10.1111\/j.1521-0391.2011.00139.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200666020-00003","article-title":"Psychiatric and substance use disorders in individuals with hepatitis C: Epidemiology and management","volume":"66","author":"Loftis","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1360-0443.2008.02188.x","article-title":"Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients","volume":"103","author":"Novick","year":"2008","journal-title":"Addiction"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB21|cit21","first-page":"157","article-title":"Influence of psychiatric diagnosis on interferon-alpha treatment for chronic hepatitis C in a veteran population","volume":"96","author":"Ho","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: An interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"issue":"S5","key":"10.1111\/j.1521-0391.2011.00139.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1086\/427442","article-title":"Addressing trimorbidity (hepatitis C, psychiatric and substance use disorders): The importance of routine mental health screening as a component of a co-management model of care","volume":"40","author":"Fireman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1572-0241.2006.00731.x","article-title":"Integrated psychiatric\/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes","volume":"101","author":"Knott","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in \u201cdifficult to treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"Litwin","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1176\/appi.psy.42.5.411","article-title":"Psychiatric comorbidity among hepatitis C positive patients","volume":"42","author":"Yovtcheva","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0376-8716(00)00144-7","article-title":"Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment","volume":"61","author":"Stein","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.mcg.0000123203.36471.70","article-title":"Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C","volume":"38","author":"Rowan","year":"2004","journal-title":"J Clin Gastroenerol"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jurban\/jth153","article-title":"Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care","volume":"81","author":"Sylvestre","year":"2004","journal-title":"J Urban Health"},{"issue":"S5","key":"10.1111\/j.1521-0391.2011.00139.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1086\/427443","article-title":"Psychiatric barriers to readiness for treatment for hepatitis C virus (HCV) infection among injection drug users: Clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital","volume":"40","author":"Scheft","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1300\/J069v27n02_07","article-title":"Obstacles to successful HCV treatment in substance addicted patients","volume":"27","author":"Cooper","year":"2008","journal-title":"J Addict Dis"},{"volume-title":"Structural Clinical Interview for DSM-IV Axis I (SCID-I)","year":"1997","author":"First","key":"10.1111\/j.1521-0391.2011.00139.x-BIB33|cit33"},{"volume-title":"Structural Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II)","year":"1997","author":"First","key":"10.1111\/j.1521-0391.2011.00139.x-BIB34|cit34"},{"volume-title":"Beck Depression Inventory","year":"1993","author":"Beck","key":"10.1111\/j.1521-0391.2011.00139.x-BIB35|cit35"},{"volume-title":"Beck Anxiety Inventory.","year":"1993","author":"Beck","key":"10.1111\/j.1521-0391.2011.00139.x-BIB36|cit36"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: Reliability, validity, and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"volume-title":"The Addiction Severity Index-\u201cLite\u201d (ASI-\u201cLite\u201d)","year":"1997","author":"McLellan","key":"10.1111\/j.1521-0391.2011.00139.x-BIB39|cit39"},{"journal-title":"SF-36 Health Survey: Manual and Interpretation Guide","year":"2000","author":"Ware","key":"10.1111\/j.1521-0391.2011.00139.x-BIB40|cit40"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/biomet\/78.3.691","article-title":"A note on a general definition of the coefficient of determination.","volume":"78","author":"Nagelkerke","year":"1991","journal-title":"Biometrika"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0376-8716(97)00117-8","article-title":"Polydrug dependence and psychiatric comorbidity among heroin injectors","volume":"48","author":"Drake","year":"1997","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsat.2006.11.013","article-title":"Co-occurring disorders in substance abuse treatment: Issues and prospects","volume":"34","author":"Flynn","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jsat.2006.05.003","article-title":"Addiction treatment services and co-occurring disorders: Prevalence estimates, treatment practices, and barriers","volume":"31","author":"McGovern","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jsat.2007.03.008","article-title":"Responding to the challenge of co-occurring disorders: Suggestions for future research","volume":"34","author":"Sacks","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"BASL Steering Committee; Benelux Study Group. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes","volume":"18","author":"Robaeys","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB100|cit47","first-page":"68","article-title":"Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice","volume":"68","author":"De Bie","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB101|cit48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2893.2005.00681.x","article-title":"Comparison of hepatitis C treatment patterns in patients with and without psychiatric and\/or substance use disorders","volume":"13","author":"Chainuvati","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB102|cit49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1176\/appi.ps.57.4.570","article-title":"Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness","volume":"57","author":"Rifai","year":"2006","journal-title":"Psych Services"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB103|cit50","first-page":"165","volume":"7","author":"Van Thiel","year":"1995","journal-title":"Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-a in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1360-0443.2009.02509.x","article-title":"Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy","volume":"104","author":"Sch\u00e4fer","year":"2009","journal-title":"Addiction"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00952999609001647","article-title":"Psychiatric morbidity: Prevalence in methadone maintenance treatment","volume":"22","author":"Milby","year":"1996","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1111\/j.1521-0391.2011.00139.x-BIB107|cit54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-2002-32713","article-title":"The prevalence of psychiatric co-morbidity among opioid addicts","volume":"29","author":"Frei","year":"2002","journal-title":"Psychiatr Prax"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1521-0391.2011.00139.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1521-0391.2011.00139.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T17:01:50Z","timestamp":1625504510000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1521-0391.2011.00139.x"}},"subtitle":["Psychiatric Diagnosis\/Symptoms in MMT w\/HCV"],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1521-0391.2011.00139.x","relation":{},"ISSN":["1055-0496"],"issn-type":[{"type":"print","value":"1055-0496"}],"subject":[],"published":{"date-parts":[[2011,5,31]]}}}